Heidi Health raised a $100M Series C in September 2026 led by Blackbird, with participation from Phoenix Court, Point72 Private Investments, and Headline, valuing the company at $900M. Alongside the equity round, Heidi secured $240M in growth financing from General Catalyst’s Customer Value Fund. The company reports $436.6M in total funding, or $196.6M excluding the growth financing.

Previously, Heidi raised a $65M Series B in October 2025 led by Point72 Private Investments at a $465M valuation. That followed a $16.6M Series A extension led by Headline in March 2025 and an A$10M Series A led by Blackbird in October 2023. Other backers across those rounds included LocalGlobe, Anthology, HESTA, Possible Ventures, and Archangel Ventures.

Originally known as Oscer, Heidi raised an A$5M seed round in 2021 led by Blackbird.

Heidi Health is an AI-powered ambient scribe that automatically generates clinical documentation during patient consultations. The platform uses real-time audio transcription to listen to doctor-patient conversations and creates structured medical notes, referral letters, and patient handouts for clinicians to review and edit.

During a consultation, Heidi's ambient microphone captures dialogue in over 110 languages and converts it into SOAP-style notes.

Beyond transcription, Ask Heidi lets clinicians work with patient context to generate summaries, referral letters, and other documents. Linked sessions and uploaded records provide additional context, while templates and coding tools adapt notes to different specialties and billing workflows. Heidi Evidence adds medical research and clinical guidance, and Dictate turns speech into text across applications.

With the September 2026 launch of Heidi II, the platform expanded into agents that help prepare information before appointments, draft referrals, and complete administrative tasks around each visit under clinician supervision. This extends Heidi from documenting the consultation to helping carry out the work it creates, with availability varying by region and subscription.

Heidi operates across multiple access points including desktop and mobile apps, a Chrome extension, and a widget that integrates with browser-based electronic health records. The Magic Paste feature allows clinicians to drop completed notes directly into their existing EHR systems with one click.

The platform maintains a privacy-first architecture where audio is streamed but not stored, with all processing occurring on privately-hosted servers that comply with ISO 27001, SOC 2, HIPAA, GDPR, and NHS-DSP standards.

Heidi operates on a B2B SaaS model targeting individual clinicians, practices, and health systems through a combination of product-led growth and enterprise sales. The platform uses freemium pricing where users can access unlimited transcription and standard note generation at no cost before upgrading to paid subscription tiers.

The company's go-to-market approach starts with bottom-up adoption where end-users, typically doctors, can adopt the product and purchase individual subscriptions directly. Heidi also sells organization-wide deployments that require IT, security, and procurement approval. This combines self-serve distribution with larger enterprise contracts.

Heidi's cost structure includes cloud infrastructure and AI model processing. More consultations per user can increase processing costs without increasing subscription revenue, making inference efficiency and conversion from free to paid plans important to its unit economics.

The business model creates expansion opportunities as practices add paid seats and adopt broader clinical and administrative tools. Users can start with basic note-taking and expand to include pre-chart summaries, coding assistance, and patient communication tools.

Revenue scales through both user acquisition and expansion into paid plans, additional seats, and higher agent usage tiers as clinicians integrate Heidi more deeply into their workflows. Paid seats include an allowance for agent tasks, with higher allowances available on Max plans. Transcription, note generation, and clinical evidence queries do not consume that allowance.

Freed is a direct competitor to Heidi Health, with both using AI documentation to win adoption from individual clinicians. Australia-based Heidi has taken a more international approach, building adoption across Australia, the UK, and other markets alongside the US, while Freed has focused primarily on US independent practices. Heidi uses free, unlimited transcription and standard note generation to encourage adoption, then sells paid clinician subscriptions and organizational contracts. Freed built its early business around a $99-per-month scribe for independent practitioners, where the doctor is often both user and buyer.

Both are expanding beyond the note. Heidi is building an AI care partner spanning documentation, clinical evidence, and agents that handle administrative work around patient visits. Freed has added Clinical Evidence, Coding Assistant, and Front Desk to serve more of the clinical and administrative work inside practices. Their products increasingly overlap, but Heidi combines self-serve adoption with sales to hospitals and health systems, while Freed’s positioning centers on independent clinics.

Abridge, Ambience, and Microsoft’s Dragon Copilot compete with Heidi for health-system deployments. These platforms combine EHR integrations with documentation, coding, and clinical workflow tools, selling to organizations where clinical, IT, and finance teams all influence purchasing decisions.

Heidi’s expansion into enterprise brings it into more direct competition with these vendors. Its free tier gives clinicians a way to adopt the product before an organization-wide purchase, but winning larger contracts still requires integrations, implementation support, and evidence of clinical and financial value. Abridge and Ambience’s expansion into revenue-cycle workflows also raises the bar beyond time saved on notes to more complete documentation and billing.

OpenEvidence combines medical search with its free Visits documentation product, while Doximity offers a free scribe alongside clinical Q&A and patient calling. Both can introduce documentation tools to clinicians already using their platforms. Because Heidi also offers free scribing, the competitive pressure falls on attracting those clinicians and giving them reasons to adopt its broader paid workflows.

Epic approaches the same use case from inside the patient record. Its native AI Charting gives health systems an alternative to bringing in another vendor, putting pressure on Heidi to demonstrate value beyond basic documentation. Heidi’s evidence tools, administrative agents, and ability to work across different EHR environments are increasingly important to that differentiation.

Heidi is expanding beyond basic transcription to become a comprehensive AI care partner for clinicians. Its evidence tools and administrative agents create opportunities to increase adoption of workflows such as pre-charting, clinical guideline lookups, and referral drafting, and convert that usage into paid subscriptions and larger organizational contracts.

The platform's developer-friendly Epic in-workflow app and API integrations position Heidi as a foundation for third-party applications like triage chatbots and referral routing systems. Platform fees and marketplace revenue represent significant TAM expansion beyond core documentation.

Specialty-specific AI playbooks for oncology, psychiatry, and other medical fields allow Heidi to command premium pricing for higher-accuracy, specialized documentation that addresses niche clinical requirements.

Heidi is building dedicated sales teams in the U.S., UK, and Canada to target large hospital systems where over 70% of clinicians still rely on legacy dictation or manual documentation. Enterprise customers represent substantially larger contract values than the company's initial SMB focus.

The veterinary market presents a parallel expansion opportunity with over 150,000 clinics globally facing similar documentation challenges but with faster purchasing cycles. Heidi's deployment with Greencross demonstrates the platform's applicability beyond human healthcare.

Existing public-health-system deployments, including NHS England Midlands, provide a base for expansion into additional organizations and broader clinical workflows. These contracts create opportunities to increase clinician adoption and sell more capabilities across public healthcare systems.

Heidi already operates in 190 countries with support for 110 languages, providing a foundation for deeper market penetration in EMEA and APAC regions. The company is establishing operational hubs in key markets to support local sales and customer success efforts.

Emerging adoption in France, Spain, Germany, South Africa, Singapore, and Hong Kong demonstrates organic international demand that can be accelerated through localized go-to-market strategies and region-specific compliance capabilities.

The global shortage of healthcare workers creates universal demand for productivity-enhancing tools like AI scribes, expanding Heidi's addressable market beyond English-speaking countries to any region with modern healthcare infrastructure.

EHR integration: While Heidi operates as a standalone solution, deeper EHR integration by incumbents like Epic and Oracle-Cerner could commoditize ambient documentation features and reduce demand for third-party solutions. Native EHR scribes bundled into existing contracts pose a significant competitive threat to independent vendors.

Regulatory scrutiny: Healthcare AI faces increasing oversight from bodies like the TGA in Australia and FDA in the United States, potentially requiring costly compliance processes or limiting product capabilities. Changes in medical liability standards for AI-generated documentation could impact adoption rates and increase operational complexity.

Margin compression: As cloud providers like AWS and Google offer ambient AI capabilities as infrastructure services, the underlying technology becomes commoditized and competition shifts toward price rather than features. Heidi's gross margins could face pressure as data processing costs remain significant while pricing power diminishes in an increasingly competitive market.